explore -WSS

explore

author：fashion 2025-09-05 13:27:11 - browse：823

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： General Catalyst, Summa Health deal will turn on physician buy

focus

WSS

ARCH Venture Partners is raising $3 billion for a life sciences fund

Woodcock on FDA’s accelerated approval and her next chapter

Glen Campbell's doctor discusses his public struggle with Alzheimer's

When prostate cancer spreads, where it goes matters

When prostate cancer spreads, where it goes matters

Cognito secures funding to test medical device for Alzheimer's

knowledge

explore

explore

Drug repurposing or repositioning? The language matters

ARCH Venture Partners is raising $3 billion for a life sciences fund

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Novavax promises a turnaround & Lilly roils the obesity market

SAMSHA loosens regulations on methadone treatment centers

Activists slam private health insurers over coverage restrictions

Medicare drug price negotiation’s day in court

Psychedelics group wrestles with new pharma identity

Do digital therapeutics have a future in medicine?

entertainment

Time to name cancers by genetics, not organ of origin, expert says

Even great ERs can’t make up for American health disparities

FDA drug safety: Singulair case shows systemic surveillance flaws

Juul spent big to court Black leaders to promote its e

Addiction experts warn against a second 'war on drugs'

General Catalyst, Summa Health deal will turn on physician buy

knowledge

focus

focus

focus